Sagimet Biosciences Inc (SGMT)

[TechandBio]

SGMT oral drug Data shows superiority to MDGL and AKRO for Nash.

3200+ patients phase 3's for NASH Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

SGMT Only Fat synthesizer oral molecule in the clinic superior to THR B & GLP1 for Nash & Obesity!


Phase 3 Nash FASCINATE-3
• 1,260 biopsy confirmed F2-F3 MASH patients
• 52 weeks, double blind, placebo-controlled

Phase 3 Up to 2,000 patients with suspected or confirmed
diagnosis of MASLD/MASH

• 52 weeks, double blind, placebo controlled

Also Pediatric Nash Trials gearing up

30% of the floating shares are short quantum squeeze is lining up!

$SGMT